Fredun Pharmaceuticals Limited, India's top formulations company, announced today a $3.2 million (INR 22 crore) contract for the sale of cardiac and anti-infectives to East African countries. The directive will be carried out over a sixteen-month period.
Mr. Fredun Medhora, Managing Director of the Fredun Group, commented on the order, saying, "We are excited to announce this significant development, which represents one of the Company's largest single orders. This order enhances our presence in the East African area, strengthening our commitment to bettering people's lives."
Fredun Pharmaceuticals Limited, a BSE-listed business, is a market leader in formulations in India. Customers throughout Africa, South East Asia, CIS countries, and Latin America rely on the Company's 34 years of competence in different pharmaceutical formulations. With operations in 42 countries, the company has significant manufacturing skills that have been authorized by numerous regulatory agencies.
Fredun Pharmaceuticals Limited shares were last trading in the BSE at Rs. 462.1, compared to the previous close of Rs. 393.05. The total number of shares exchanged in over 2506 deals during the day was 132811.